Kyntra Bio said it completed the sale of FibroGen China to AstraZeneca for approximately USD 220 million. The company said it repaid a term loan to Morgan Stanley Tactical Value and extended its cash runway into 2028. Kyntra Bio said its Phase 2 monotherapy trial of FG-3246 and FG-3180 in metastatic castration-resistant prostate cancer is enrolling, with interim results expected in 2H 2026. The presentation said FG-3246 is a CD46-targeting antibody-drug conjugate and FG-3180 is a PET imaging agent being developed as a patient selection biomarker.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kyntra Bio Inc. published the original content used to generate this news brief on March 11, 2026, and is solely responsible for the information contained therein.